Inflammatory cytokines in patients with common mental disorders treated with cognitive behavior therapy.
Cognitive behavior therapy
Common mental disorders
Cytokines
Inflammation
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
03
02
2020
accepted:
03
02
2020
entrez:
30
9
2021
pubmed:
5
2
2020
medline:
5
2
2020
Statut:
epublish
Résumé
Peripheral inflammation has been found associated with psychiatric disorders. However, results are inconclusive as to its role in common mental disorders (CMDs), i.e., depression, anxiety, insomnia and stress-related disorders. Further, some research suggests that cognitive behavior therapy (CBT) could reduce inflammatory markers in CMDs. In the present study, we measured pro-inflammatory cytokines (tumor necrosis factor alpha [TNF-α], interleukin-6 [IL-6] and IL-8) pre- and post-treatment in two clinical trials (N = 367) investigating CBT for patients with CMDs in primary care. We hypothesized that higher levels of these cytokines would be associated with more severe psychiatric symptoms (i.e., symptoms of depression, stress and anxiety). We also hypothesized that level of cytokines would decrease after CBT and that the reduced levels would correlate with a reduction in symptoms. Results showed that in men, higher levels of TNF-α were associated with more severe psychiatric symptoms. Further, age moderated the association between TNF-α, as well as IL-6, and stress, and exploratory stratified analyses revealed significant associations in subgroups. No other significant associations between cytokines and psychiatric symptoms were found. None of the cytokines were reduced following CBT, and the marked improvements in psychiatric symptoms after treatment were not associated with changes in cytokines. In conclusion, although inflammation might be of relevance in subgroups, it seems to be of limited importance for clinical improvements across mild to moderate CMDs.
Identifiants
pubmed: 34589836
doi: 10.1016/j.bbih.2020.100045
pii: S2666-3546(20)30010-7
pmc: PMC8474381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100045Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
JAMA Psychiatry. 2013 Jan;70(1):31-41
pubmed: 22945416
Acta Psychiatr Scand. 2016 Jul;134(1):40-7
pubmed: 27028967
J Neuroimmunol. 2015 Aug 15;285:143-6
pubmed: 26198931
Nord J Psychiatry. 2008;62 Suppl 47:5-10
pubmed: 18752112
Am J Cardiol. 2002 Dec 15;90(12):1279-83
pubmed: 12480034
PLoS One. 2016 May 27;11(5):e0156624
pubmed: 27232630
Front Neuroendocrinol. 2018 Jul;50:91-106
pubmed: 29935190
Annu Rev Psychol. 2015 Jan 3;66:143-72
pubmed: 25061767
Can J Psychiatry. 2013 Jul;58(7):376-85
pubmed: 23870719
Occup Environ Med. 2017 Dec;74(12):905-912
pubmed: 28756415
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Neuroscience. 2013 Aug 29;246:199-229
pubmed: 23644052
Br J Psychiatry. 2008 May;192(5):368-75
pubmed: 18450663
Brain Behav Immun. 2015 Oct;49:206-15
pubmed: 26065825
J Environ Public Health. 2012;2012:515874
pubmed: 22496705
Aust N Z J Psychiatry. 2017 Jun;51(6):565-582
pubmed: 28382827
J Psychosom Res. 2003 Oct;55(4):309-16
pubmed: 14507541
Transl Psychiatry. 2017 May 16;7(5):e1132
pubmed: 28509904
Br J Psychiatry. 2007 Apr;190:326-32
pubmed: 17401039
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Curr Psychiatry Rep. 2014 Jun;16(6):451
pubmed: 24748555
Curr Psychiatry Rep. 2011 Dec;13(6):467-75
pubmed: 21927805
Scand J Psychol. 2015 Dec;56(6):626-36
pubmed: 26496458
Immunol Allergy Clin North Am. 2009 May;29(2):247-64
pubmed: 19389580
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Brain Behav Immun. 2007 Feb;21(2):153-60
pubmed: 17088043
Brain Behav Immun. 2018 Jan;67:1-12
pubmed: 28216088
BMC Med. 2013 Sep 12;11:200
pubmed: 24228900
Scand J Psychol. 2014 Feb;55(1):72-82
pubmed: 24236500
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Trends Immunol. 2006 Jan;27(1):24-31
pubmed: 16316783
Neuropsychopharmacology. 2011 Nov;36(12):2452-9
pubmed: 21796103
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Acta Psychiatr Scand. 1994 Jan;89(1):21-8
pubmed: 8140903
Eur Psychiatry. 2011 Sep;26(6):363-9
pubmed: 21570260
Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559
pubmed: 28479211
Rehabil Psychol. 2011 Nov;56(4):267-88
pubmed: 21967118
Psychol Med. 2018 Jul;48(10):1644-1654
pubmed: 29095133
PLoS One. 2016 Nov 10;11(11):e0165799
pubmed: 27832117
Brain Behav Immun. 2014 Aug;40:235-43
pubmed: 24726793
Lancet. 2012 Mar 24;379(9821):1129-41
pubmed: 22265700
Immunol Res. 2014 May;58(2-3):193-210
pubmed: 24798553
Psychiatry Res. 2013 Oct 30;209(3):742-5
pubmed: 23541242
Am J Psychiatry. 2005 Jan;162(1):175-7
pubmed: 15625217
Curr Psychiatry Rep. 2012 Jun;14(3):220-8
pubmed: 22477442
J Neuroimmunol. 2010 Dec 15;229(1-2):212-8
pubmed: 20709414
Brain Behav Immun. 2014 Jan;35:1-8
pubmed: 24491305
Ann Intern Med. 2015 Aug 4;163(3):191-204
pubmed: 26054060
Depress Anxiety. 2018 Nov;35(11):1081-1094
pubmed: 30199144
Nat Rev Immunol. 2008 Sep;8(9):737-44
pubmed: 18728636
Occup Environ Med. 2018 Feb;75(2):105-113
pubmed: 28855344
Scand J Psychol. 2017 Dec;58(6):551-561
pubmed: 29105127
Psychother Psychosom. 2018;87(5):296-305
pubmed: 30041167
Psychiatry Res. 2017 Aug;254:311-316
pubmed: 28501736
Nat Rev Immunol. 2013 Mar;13(3):190-8
pubmed: 23391992